Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 315

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 315
---
 targets and 100 shares of which are subject to vesting upon a change of control, respectively.                               |

| 4. | Certain                                                                                                                    
 holders of Predecessor’s common stock received a pro rata portion                                                          
 of 438 earnout shares of Common Stock (the “Reallocation Shares”), valued at $4.29 million, which became fully vested upon 
 the Closing.                                                                                                               |

| 5. | Certain holders of Predecessor’s common stock and convertible                                                                
 bridge notes received a pro rata portion of 500 earnout shares (the “IND Earnout shares”) of restricted Common Stock, valued 
 at $4,900,000, which vested when the Company filed an investigational new drug (“IND”) application with the Food and Drug    
 Administration (“FDA”). The earning of these shares was accompanied by a forfeiture of 500 restricted shares of Common Stock 
 held by the sponsor following receipt of an acknowledgement notice by the Sponsor.                                           |

| 6. | Each                                                                                                                                            
 outstanding Predecessor option was converted into an option to purchase a number of shares of Common Stock, equal to the Predecessor’s          
 common stock underlying the option multiplied by the Exchange Ratio factor of 0.064452, at an exercise price per share equal to the Predecessor 
 option exercise price divided by the Exchange Ratio factor.                                                                                     |

| 7. | Each                                                                                                                                         
 warrant to purchase the Predecessor’s preferred stock was converted into a warrant to acquire a number of shares of Common Stock             
 obtained by dividing the warrant as-if-exercised liquidation preference by $1,000.00, with the exercise price equal to the total Predecessor 
 warrant exercise amount divided by the number of shares of Common Stock issuable upon exercise.                                              |

| 8. | The                                                                                                                         
 Predecessor’s bridge notes automatically converted into shares of the Company’s Series A Preferred Stock, par value $0.0001 
 per share (the “Series A Preferred Stock”), at a conversion price equal to $750 per share of Series A Preferred Stock.      |

The Company issued, transferred from the Sponsor, or reserved for issuance
an aggregate of shares of Common Stock to the holders of Predecessor common stock and Predecessor preferred stock or reserved for
issuance upon exercise of rollover (from Predecessor to Successor) options and warrants as consideration in the Merger.

F-12

Asset Acquisition Method of Accounting
- The Merger was accounted for using